Molecular basis of the Keap1-Nrf2 system

Free Radical Biology and Medicine

Volumn 88, Issue Part B, 2015, Pages 93-100

  Suzuki, Takafumi ^a   Yamamoto, Masayuki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinogenesis; Chemical inducers; Free radicals; Keap1; Nrf2; Stress response

Indexed keywords

ANTINEOPLASTIC AGENT; CYSTEINE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3; SIGNAL PEPTIDE;

CANCER CELL; CANCER RESISTANCE; CARCINOGENESIS; ELECTROPHILIC STRESS; HUMAN; IN VIVO STUDY; METASTASIS; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION;

EID: 84971291437     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2015.06.006     Document Type: Review

References (83)

1. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, and Y. Nabeshima An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements Biochem. Biophys. Res. Commun. 236 1997 313 322
2. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, and M. Yamamoto Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Genes Dev. 13 1999 76 86
3. H. Motohashi, and M. Yamamoto Nrf2-Keap1 defines a physiologically important stress response mechanism Trends Mol. Med. 10 2004 549 557
4. T. Suzuki, H. Motohashi, and M. Yamamoto Toward clinical application of the Keap1-Nrf2 pathway Trends Pharmacol. Sci. 34 2013 340 346
5. K. Itoh, T. Ishii, N. Wakabayashi, and M. Yamamoto Regulatory mechanisms of cellular response to oxidative stress Free Radic. Res. 31 1999 319 324
6. J.D. Hayes, and A.T. Dinkova-Kostova The Nrf2 regulatory network provides an interface between redox and intermediary metabolism Trends Biochem. Sci. 39 2014 199 218
7. A. Kobayashi, M.I. Kang, H. Okawa, M. Ohtsuji, Y. Zenke, T. Chiba, K. Igarashi, and M. Yamamoto Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2 Mol. Cell. Biol. 24 2004 7130 7139
8. N. Wakabayashi, K. Itoh, J. Wakabayashi, H. Motohashi, S. Noda, S. Takahashi, S. Imakado, T. Kotsuji, F. Otsuka, D.R. Roop, T. Harada, J.D. Engel, and M. Yamamoto Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation Nat. Genet. 35 2003 238 245
9. K. Taguchi, J.M. Maher, T. Suzuki, Y. Kawatani, H. Motohashi, and M. Yamamoto Genetic analysis of cytoprotective functions supported by graded expression of Keap1 Mol. Cell. Biol. 30 2010 3016 3026
10. T.W. Kensler, and N. Wakabayashi Nrf2: friend or foe for chemoprevention? Carcinogenesis 31 2010 90 99
11. A.T. Dinkova-Kostova, and R.V. Kostov Glucosinolates and isothiocyanates in health and disease Trends Mol. Med. 18 2012 337 347
12. A.T. Dinkova-Kostova, and P. Talalay Direct and indirect antioxidant properties of inducers of cytoprotective proteins Mol. Nutr. Food Res. 52 Suppl. 1 2008 S128 138
13. A.T. Dinkova-Kostova, W.D. Holtzclaw, R.N. Cole, K. Itoh, N. Wakabayashi, Y. Katoh, M. Yamamoto, and P. Talalay Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants Proc. Natl. Acad. Sci. USA 99 2002 11908 11913
14. M. Kobayashi, L. Li, N. Iwamoto, Y. Nakajima-Takagi, H. Kaneko, Y. Nakayama, M. Eguchi, Y. Wada, Y. Kumagai, and M. Yamamoto The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds Mol. Cell. Biol. 29 2009 493 502
15. D.D. Zhang, and M. Hannink Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress Mol. Cell. Biol. 23 2003 8137 8151
16. T. Yamamoto, T. Suzuki, A. Kobayashi, J. Wakabayashi, J. Maher, H. Motohashi, and M. Yamamoto Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity Mol. Cell. Biol. 28 2008 2758 2770
17. K. Takaya, T. Suzuki, H. Motohashi, K. Onodera, S. Satomi, T.W. Kensler, and M. Yamamoto Validation of the multiple sensor mechanism of the Keap1-Nrf2 system Free Radic. Biol. Med. 53 2012 817 827
18. K.I. Tong, A. Kobayashi, F. Katsuoka, and M. Yamamoto Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism Biol. Chem. 387 2006 1311 1320
19. K.I. Tong, B. Padmanabhan, A. Kobayashi, C. Shang, Y. Hirotsu, S. Yokoyama, and M. Yamamoto Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response Mol. Cell. Biol. 27 2007 7511 7521
20. T. Fukutomi, K. Takagi, T. Mizushima, N. Ohuchi, and M. Yamamoto Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1 Mol. Cell. Biol. 34 2014 832 846
21. B. Padmanabhan, K.I. Tong, T. Ohta, Y. Nakamura, M. Scharlock, M. Ohtsuji, M.I. Kang, A. Kobayashi, S. Yokoyama, and M. Yamamoto Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer Mol. Cell 21 2006 689 700
22. L. Baird, D. Llères, S. Swift, and A.T. Dinkova-Kostova Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex Proc. Natl. Acad. Sci. USA 110 2013 15259 15264
23. B.E. Hast, E.W. Cloer, D. Goldfarb, H. Li, P.F. Siesser, F. Yan, V. Walter, N. Zheng, D.N. Hayes, and M.B. Major Cancer-derived mutations in Keap1 impair Nrf2 degradation but not ubiquitination Cancer Res. 74 2014 808 817
24. T. Ogura, K.I. Tong, K. Mio, Y. Maruyama, H. Kurokawa, C. Sato, and M. Yamamoto Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains Proc. Natl. Acad. Sci. USA 107 2010 2842 2847
25. D.D. Zhang, S.C. Lo, J.V. Cross, D.J. Templeton, and M. Hannink Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex Mol. Cell. Biol. 24 2004 10941 10953
26. L. Gao, J. Wang, K.R. Sekhar, H. Yin, N.F. Yared, S.N. Schneider, S. Sasi, T.P. Dalton, M.E. Anderson, J.Y. Chan, J.D. Morrow, and M.L. Freeman Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3 J. Biol. Chem. 282 2007 2529 2537
27. G. Rachakonda, Y. Xiong, K.R. Sekhar, S.L. Stamer, D.C. Liebler, and M.L. Freeman Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3 Chem. Res. Toxicol. 21 2008 705 710
28. K.T. Liby, and M.B. Sporn Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease Pharmacol. Rev. 64 2012 972 1003
29. P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, E.B. Grossman, M. Krauth, S. Ruiz, P. Audhya, H. Christ-Schmidt, J. Wittes, and D.G. Warnock Investigators, B. S. Bardoxolone methyl and kidney function in CKD with type 2 diabetes N. Engl. J. Med. 365 2011 327 336
30. D. de Zeeuw, T. Akizawa, P. Audhya, G.L. Bakris, M. Chin, H. Christ-Schmidt, A. Goldsberry, M. Houser, M. Krauth, Heerspink Lambers, H.J. McMurray, J. J., C.J. Meyer, H.H. Parving, G. Remuzzi, R.D. Toto, N.D. Vaziri, C. Wanner, J. Wittes, D. Wrolstad, and G.M. Chertow Investigators, B. T. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease N. Engl. J. Med. 369 2013 2492 2503
31. L. Hu, S. Magesh, L. Chen, L. Wang, T.A. Lewis, Y. Chen, C. Khodier, D. Inoyama, L.J. Beamer, T.J. Emge, J. Shen, J.E. Kerrigan, A.N. Kong, S. Dandapani, M. Palmer, S.L. Schreiber, and B. Munoz Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction Bioorg. Med. Chem. Lett. 23 2013 3039 3043
32. D. Marcotte, W. Zeng, J.C. Hus, A. McKenzie, C. Hession, P. Jin, C. Bergeron, A. Lugovskoy, I. Enyedy, H. Cuervo, D. Wang, C. Atmanene, D. Roecklin, M. Vecchi, V. Vivat, J. Kraemer, D. Winkler, V. Hong, J. Chao, M. Lukashev, and L. Silvian Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism Bioorg. Med. Chem. 21 2013 4011 4019
33. A. Ohkoshi, T. Suzuki, M. Ono, T. Kobayashi, and M. Yamamoto Roles of Keap1-Nrf2 system in upper aerodigestive tract carcinogenesis Cancer Prev. Res. (Philadelphia) 6 2013 149 159
34. D. Kanojia, and M.M. Vaidya 4-Nitroquinoline-1-oxide induced experimental oral carcinogenesis Oral Oncol. 42 2006 655 667
35. C.S. Morrow, P.K. Smitherman, S.K. Diah, E. Schneider, and A.J. Townsend Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification: mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells J. Biol. Chem. 273 1998 20114 20120
36. Y. Yagishita, T. Fukutomi, A. Sugawara, H. Kawamura, T. Takahashi, J. Pi, A. Uruno, and M. Yamamoto. Nrf2 protects pancreatic β-cells from oxidative and nitrosative stress in diabetic model mice Diabetes 63 2014 605 618
37. A. Uruno, Y. Furusawa, Y. Yagishita, T. Fukutomi, H. Muramatsu, T. Negishi, A. Sugawara, T.W. Kensler, and M. Yamamoto The Keap1-Nrf2 system prevents onset of diabetes mellitus Mol. Cell. Biol. 33 2013 2996 3010
38. A. Uruno, Y. Yagishita, and M. Yamamoto The Keap1-Nrf2 system and diabetes mellitus Arch. Biochem. Biophys. 566 2015 76 84
39. A.K. Meher, P.R. Sharma, V.A. Lira, M. Yamamoto, T.W. Kensler, Z. Yan, and N. Leitinger Nrf2 deficiency in myeloid cells is not sufficient to protect mice from high-fat diet-induced adipose tissue inflammation and insulin resistance Free Radic. Biol. Med. 52 2012 1708 1715
40. Y.K. Zhang, K.C. Wu, J. Liu, and C.D. Klaassen Nrf2 deficiency improves glucose tolerance in mice fed a high-fat diet Toxicol. Appl. Pharmacol. 264 2012 305 314
41. P.J. Meakin, S. Chowdhry, R.S. Sharma, F.B. Ashford, S.V. Walsh, R.J. McCrimmon, A.T. Dinkova-Kostova, J.F. Dillon, J.D. Hayes, and M.L. Ashford Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance Mol. Cell. Biol. 34 2014 3305 3320
42. Y. Furusawa, A. Uruno, Y. Yagishita, C. Higashi, and M. Yamamoto Nrf2 induces fibroblast growth factor 21 in diabetic mice Genes Cells 19 2014 864 878
43. P.K. Saha, V.T. Reddy, M. Konopleva, M. Andreeff, and L. Chan The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice J. Biol. Chem. 285 2010 40581 40592
44. J. Xu, A.C. Donepudi, J.E. Moscovitz, and A.L. Slitt Keap1-knockdown decreases fasting-induced fatty liver via altered lipid metabolism and decreased fatty acid mobilization from adipose tissue PLoS One 8 2013 e79841
45. M. Ramos-Gomez, M.K. Kwak, P.M. Dolan, K. Itoh, M. Yamamoto, P. Talalay, and T.W. Kensler Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice Proc. Natl. Acad. Sci. USA 98 2001 3410 3415
46. K. Iida, K. Itoh, Y. Kumagai, R. Oyasu, K. Hattori, K. Kawai, T. Shimazui, H. Akaza, and M. Yamamoto Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis Cancer Res. 64 2004 6424 6431
47. C. Xu, M.T. Huang, G. Shen, X. Yuan, W. Lin, T.O. Khor, A.H. Conney, and A.N. Kong Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2 Cancer Res. 66 2006 8293 8296
48. Y. Kitamura, T. Umemura, K. Kanki, Y. Kodama, S. Kitamoto, K. Saito, K. Itoh, M. Yamamoto, T. Masegi, A. Nishikawa, and M. Hirose Increased susceptibility to hepatocarcinogenicity of Nrf2-deficient mice exposed to 2-amino-3-methylimidazo[4,5-f]quinoline Cancer Sci. 98 2007 19 24
49. T.O. Khor, M.T. Huang, A. Prawan, Y. Liu, X. Hao, S. Yu, W.K. Cheung, J.Y. Chan, B.S. Reddy, C.S. Yang, and A.N. Kong Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer Cancer Prev. Res. (Philadelphia) 1 2008 187 191
50. L. Becks, M. Prince, H. Burson, C. Christophe, M. Broadway, K. Itoh, M. Yamamoto, M. Mathis, E. Orchard, R. Shi, J. McLarty, K. Pruitt, S. Zhang, and H.E. Kleiner-Hancock Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene BMC Cancer 10 2010 540
51. T. Yamamoto, K. Yoh, A. Kobayashi, Y. Ishii, S. Kure, A. Koyama, T. Sakamoto, K. Sekizawa, H. Motohashi, and M. Yamamoto Identification of polymorphisms in the promoter region of the human Nrf2 gene Biochem. Biophys. Res. Commun. 321 2004 72 79
52. J.M. Marzec, J.D. Christie, S.P. Reddy, A.E. Jedlicka, H. Vuong, P.N. Lanken, R. Aplenc, T. Yamamoto, M. Yamamoto, H.Y. Cho, and S.R. Kleeberger Functional polymorphisms in the transcription factor Nrf2 in humans increase the risk of acute lung injury FASEB J 21 2007 2237 2246
53. T. Suzuki, T. Shibata, K. Takaya, K. Shiraishi, T. Kohno, H. Kunitoh, K. Tsuta, K. Furuta, K. Goto, F. Hosoda, H. Sakamoto, H. Motohashi, and M. Yamamoto Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels Mol. Cell. Biol. 33 2013 2402 2412
54. A.K. Bauer, H.Y. Cho, L. Miller-Degraff, C. Walker, K. Helms, J. Fostel, M. Yamamoto, and S.R. Kleeberger Targeted deletion of Nrf2 reduces urethane-induced lung tumor development in mice PLoS One 6 2011 e26590
55. H. Satoh, T. Moriguchi, J. Takai, M. Ebina, and M. Yamamoto Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis Cancer Res. 73 2013 4158 4168
56. Y. Okano, U. Nezu, Y. Enokida, M.T. Lee, H. Kinoshita, A. Lezhava, Y. Hayashizaki, S. Morita, M. Taguri, Y. Ichikawa, T. Kaneko, Y. Natsumeda, T. Yokose, H. Nakayama, Y. Miyagi, and T. Ishikawa SNP (-617C>A) in ARE-like loci of the Nrf2 gene: a new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women PLoS One 8 2013 e73794
57. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji, T. Suzuki, A. Kobayashi, J. Yokota, T. Sakiyama, T. Shibata, M. Yamamoto, and S. Hirohashi Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Res. 68 2008 1303 1309
58. T. Shibata, A. Kokubu, M. Gotoh, H. Ojima, T. Ohta, M. Yamamoto, and S. Hirohashi Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer Gastroenterology 135 2008 1358 1368
59. T. Shibata, T. Ohta, K.I. Tong, A. Kokubu, R. Odogawa, K. Tsuta, H. Asamura, M. Yamamoto, and S. Hirohashi Cancer related mutations in Nrf2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Proc. Natl. Acad. Sci. USA 105 2008 13568 13573
60. Y.R. Kim, J.E. Oh, M.S. Kim, M.R. Kang, S.W. Park, J.Y. Han, H.S. Eom, N.J. Yoo, and S.H. Lee Oncogenic Nrf2 mutations in squamous cell carcinomas of oesophagus and skin J. Pathol. 220 2010 446 451
61. L.A. Muscarella, P. Parrella, V. D'Alessandro, A. la Torre, R. Barbano, A. Fontana, A. Tancredi, V. Guarnieri, T. Balsamo, M. Coco, M. Copetti, F. Pellegrini, P. De Bonis, M. Bisceglia, G. Scaramuzzi, E. Maiello, V.M. Valori, G. Merla, G. Vendemiale, and V.M. Fazio Frequent epigenetics inactivation of Keap1 gene in non-small cell lung cancer Epigenetics 6 2011 710 719
62. J. Adam, E. Hatipoglu, L. O'Flaherty, N. Ternette, N. Sahgal, H. Lockstone, D. Baban, E. Nye, G.W. Stamp, K. Wolhuter, M. Stevens, R. Fischer, P. Carmeliet, P.H. Maxwell, C.W. Pugh, N. Frizzell, T. Soga, B.M. Kessler, M. El-Bahrawy, P.J. Ratcliffe, and P.J. Pollard Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in Keap1 succination and Nrf2 signaling Cancer Cell 20 2011 524 537
63. A. Ooi, J.C. Wong, D. Petillo, D. Roossien, V. Perrier-Trudova, D. Whitten, B.W. Min, M.H. Tan, Z. Zhang, X.J. Yang, M. Zhou, B. Gardie, V. Molinié, S. Richard, P.H. Tan, B.T. Teh, and K.A. Furge An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma Cancer Cell 20 2011 511 523
64. G.M. DeNicola, F.A. Karreth, T.J. Humpton, A. Gopinathan, C. Wei, K. Frese, D. Mangal, K.H. Yu, C.J. Yeo, E.S. Calhoun, F. Scrimieri, J.M. Winter, R.H. Hruban, C. Iacobuzio-Donahue, S.E. Kern, I.A. Blair, and D.A. Tuveson Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis Nature 475 2011 106 109
65. S.L. Slocum, and T.W. Kensler Nrf2: control of sensitivity to carcinogens Arch. Toxicol. 85 2011 273 284
66. Y. Mitsuishi, K. Taguchi, Y. Kawatani, T. Shibata, T. Nukiwa, H. Aburatani, M. Yamamoto, and H. Motohashi Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming Cancer Cell 22 2012 66 79
67. D. Deeb, X. Gao, Y. Liu, D. Jiang, G.W. Divine, A.S. Arbab, S.A. Dulchavsky, and S.C. Gautam Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling Carcinogenesis 32 2011 757 764
68. X. Gao, D. Deeb, Y. Liu, A.S. Arbab, G.W. Divine, S.A. Dulchavsky, and S.C. Gautam Prevention of prostate cancer with oleanane synthetic triterpenoid CDDO-Me in the TRAMP mouse model of prostate cancer Cancers 3 2011 Basel 3353 3369
69. K. Tran, R. Risingsong, D. Royce, C.R. Williams, M.B. Sporn, and K. Liby The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice Cancer Prev. Res. (Philadelphia) 5 2012 726 734
70. D.S. Hong, R. Kurzrock, J.G. Supko, X. He, A. Naing, J. Wheler, D. Lawrence, J.P. Eder, C.J. Meyer, D.A. Ferguson, J. Mier, M. Konopleva, S. Konoplev, M. Andreeff, D. Kufe, H. Lazarus, G.I. Shapiro, and B.J. Dezube A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas Clin. Cancer Res. 18 2012 3396 3406
71. Y.Y. Wang, Y.X. Yang, H. Zhe, Z.X. He, and S.F. Zhou Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties Drug Des. Dev. Ther 8 2014 2075 2088
72. S. Nagaraj, J.I. Youn, H. Weber, C. Iclozan, L. Lu, M.J. Cotter, C. Meyer, C.R. Becerra, M. Fishman, S. Antonia, M.B. Sporn, K.T. Liby, B. Rawal, J.H. Lee, and D.I. Gabrilovich Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer Clin. Cancer Res. 16 2010 1812 1823
73. H. Satoh, T. Moriguchi, K. Taguchi, J. Takai, J.M. Maher, T. Suzuki, P.T. Winnard, V. Raman, M. Ebina, T. Nukiwa, and M. Yamamoto Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung Carcinogenesis 31 2010 1833 1843
74. K. Hiramoto, H. Satoh, T. Suzuki, T. Moriguchi, J. Pi, T. Shimosegawa, and M. Yamamoto Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis Cancer Prev. Res. (Philadelphia) 7 2014 835 844
75. P. Rada, A.I. Rojo, S. Chowdhry, M. McMahon, J.D. Hayes, and A. Cuadrado SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner Mol. Cell. Biol. 31 2011 1121 1133
76. S. Chowdhry, Y. Zhang, M. McMahon, C. Sutherland, A. Cuadrado, and J.D. Hayes Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity Oncogene 32 2013 3765 3781
77. K. Taguchi, I. Hirano, T. Itoh, M. Tanaka, A. Miyajima, A. Suzuki, H. Motohashi, and M. Yamamoto Nrf2 enhances cholangiocyte expansion in Pten-deficient livers Mol. Cell. Biol. 34 2014 900 913
78. K.N. Lewis, E. Wason, Y.H. Edrey, D.M. Kristan, E. Nevo, and R. Buffenstein Regulation of Nrf2 signaling and longevity in naturally long-lived rodents Proc. Natl. Acad. Sci. USA 112 2015 3722 3727
79. A.I. Rojo, P. Rada, M. Mendiola, A. Ortega-Molina, K. Wojdyla, A. Rogowska-Wrzesinska, D. Hardisson, M. Serrano, and A. Cuadrado The PTEN/Nrf2 axis promotes human carcinogenesis Antioxid. Redox Signaling 21 2014 2498 2514
80. M. Komatsu, H. Kurokawa, S. Waguri, K. Taguchi, A. Kobayashi, Y. Ichimura, Y.S. Sou, I. Ueno, A. Sakamoto, K.I. Tong, M. Kim, Y. Nishito, S. Iemura, T. Natsume, T. Ueno, E. Kominami, H. Motohashi, K. Tanaka, and M. Yamamoto The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 Nat. Cell Biol. 12 2010 213 223
81. Y. Ichimura, S. Waguri, Y.S. Sou, S. Kageyama, J. Hasegawa, R. Ishimura, T. Saito, Y. Yang, T. Kouno, T. Fukutomi, T. Hoshii, A. Hirao, K. Takagi, T. Mizushima, H. Motohashi, M.S. Lee, T. Yoshimori, K. Tanaka, M. Yamamoto, and M. Komatsu Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy Mol. Cell 51 2013 618 631
82. Y. Inami, S. Waguri, A. Sakamoto, T. Kouno, K. Nakada, O. Hino, S. Watanabe, J. Ando, M. Iwadate, M. Yamamoto, M.S. Lee, K. Tanaka, and M. Komatsu Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells J. Cell Biol. 193 2011 275 284
83. K. Taguchi, N. Fujikawa, M. Komatsu, T. Ishii, M. Unno, T. Akaike, H. Motohashi, and M. Yamamoto Keap1 degradation by autophagy for the maintenance of redox homeostasis Proc. Natl. Acad. Sci. USA 109 2012 13561 13566